A new publication by Prof. Francesco Bertoni LAB

Antibody-drug conjugates (ADCs) are an effective therapeutic modality to deliver potent cytotoxic molecules to tumor cells bearing a specific antigen. Following their previous work on the anti-CD19 ADCs huB4-DGN462 and coltuximab ravtansine (SAR3419) (PMID 30733273), the research team led by Prof. Francesco Bertoni has now characterized the novel ADC MEN1309/OBT076 targeting CD205 for its anti- ly...
More

New publication by Giuseppina Carbone’s Prostate Cancer Biology group

A new study, published in the journal Cancers describes a novel approach to dissect the intrinsic heterogeneity of prostate tumors and provide predictive information on clinical outcome and treatment response in clinical samples and experimental models. This prostate-specific metagene approach can improve treatment selection and clinical management of prostate cancer patients. Sarah N. Mapelli,...
More

Mitochondrial reprogramming heads stem cell expansion and castration-resistance in prostate cancer – New grant awarded to Prof. Carlo Catapano

New grant awarded by the Swiss Cancer League to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano. The 3-year project aims at exploring the role of mitochondria in prostate cancer progression and resistance to current therapies. Project details Project ID: KLS-4899-08-2019 PI: Carlo Catapano Project title: Mitochondrial dynamics at the...
More

Combinatorial nanomedicines for precision therapy of prostate cancer at the IOR – New grant awarded to Prof. Carlo Catapano

New grant awarded to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Director Prof. Carlo Catapano (http://www.ior.usi.ch). The project Nanoparticle-based delivery and combinatorial therapies for cancer funded by SNSF in the context of the European COST action on Cancer Nanomedicine (CA17140) aims at developing new nanoparticle-based medicine for precision therapy of adv...
More

Full professorship at ETH Zurich granted to Prof. Dr. Andrea Alimonti

Professor Andrea Alimonti, MD, group leader at the Institute of Oncology Research (IOR, affiliated with USI) and Full professor at the USI Faculty of Biomedical Sciences, has been appointed by the ETH Board as Full professor of Experimental oncology and translational cancer medicine at the ETH Zurich. https://www.usi.ch/en/feeds/12525 https://ethz.ch/en/news-and-events/eth-news/news/2019/12/...
More

Robert Wenner Prize to Andrea Alimonti

The Swiss Cancer League has awarded this year's Robert Wenner Prize for young cancer researchers to Andrea Alimonti. With his work, the researcher and doctor has discovered how cancer cells age - and how this so-called senescence can be used therapeutically. More information on the Robert Wenner Prize
More